UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma

NCT00580372 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

231

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: VAD
DRUG: High-Dose cyclophosphamide
PROCEDURE: Hemopoietic stem cell procurement
DRUG: EDAP
PROCEDURE: Autologous Hemopoietic Stem Cell Transplant 1
PROCEDURE: Autologous Hemopoietic Stem Cell Transplant 2
DRUG: Maintenance

Sponsor

University of Arkansas